Luye Pharma Group (FRA:LUP) ROCE %: 7.79% (As of Dec. 2025)


FRA:LUP Luye Pharma Group Ltd FRA:LUP
47 GF Score
Price €0.20
GF Value €0.32
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Luye Pharma Group ROCE %?

Luye Pharma Group FRA:LUP +3.03% 47 ROCE % is 7.79% as of Dec. 2025. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Luye Pharma Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 7.79%.

Luye Pharma Group  (FRA:LUP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Luye Pharma Group ROCE % Related Terms

Luye Pharma Group ROCE % Historical Data

* Premium members only.

The historical data trend for Luye Pharma Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Luye Pharma Group ROCE % Chart

Luye Pharma Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 7.51 8.36 7.82 7.54

Luye Pharma Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.40 9.28 6.62 7.85 7.79
FRA:LUP
47GF Score
Luye Pharma Group Ltd FRA:LUP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Luye Pharma Group ROCE % Calculation

Luye Pharma Group's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=197.79/( ( (3884.194 - 1412.574) + (3980.128 - 1204.734) )/ 2 )
=197.79/( (2471.62+2775.394)/ 2 )
=197.79/2623.507
=7.54 %

Luye Pharma Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=202.522/( ( (3867.651 - 1441.582) + (3980.128 - 1204.734) )/ 2 )
=202.522/( ( 2426.069 + 2775.394 )/ 2 )
=202.522/2600.7315
=7.79 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.79% mean?
Luye Pharma Group (FRA:LUP) has a ROCE % of 7.79% as of Dec. 2025.
Is Luye Pharma Group's ROCE % too high?
Luye Pharma Group's current ROCE % is 7.79%. The Drug Manufacturers industry median ROCE % is 7.03. Luye Pharma Group's value of 7.79% is 10.8% above this industry median. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's ROCE % compare to ZTS and UTHR?
Luye Pharma Group's ROCE % of 7.79% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Luye Pharma Group's value of 7.79% is 10.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Luye Pharma Group's current ROCE % of 7.79% is 10.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current ROCE % is 7.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current ROCE % is 7.79% and 10.8% above the Drug Manufacturers industry median of 7.03. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current ROCE % is 7.79% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?

Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued. The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32. GuruFocus considers Luye Pharma Group to be Possible Value Trap.

Key valuation signals for FRA:LUP:

  • ROCE %: 7.79%
  • GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
  • GF Score™: 47/100 with 5 warning signs
  • Industry Position: 10.8% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Luye Pharma Group Business Description

Other Exchanges LYPHF:USA02186:Hong Kong
Address Hongqiao Road 1438, 22nd Floor, Gubei International Fortune Center II, Changning District, Shanghai, CHN
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score

Get the complete analysis for FRA:LUP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€0.32
GF Value